Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antisense oligonucleotide |
| gptkbp:ATCCode |
L01XX35
|
| gptkbp:CASNumber |
190977-41-4
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
Genta Incorporated
|
| gptkbp:hasMolecularFormula |
C190H244N60O59P19S19
|
| https://www.w3.org/2000/01/rdf-schema#label |
oblimersen
|
| gptkbp:investigatedBy |
melanoma
multiple myeloma chronic lymphocytic leukemia |
| gptkbp:IUPACName |
phosphorothioate oligonucleotide (sequence: 5'-TCTCCCAGCGTGCGCCAT-3')
|
| gptkbp:mechanismOfAction |
inhibits Bcl-2 protein expression
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:synonym |
G3139
Genasense |
| gptkbp:target |
BCL2 mRNA
|
| gptkbp:UNII |
6M8XEZD5QK
|
| gptkbp:bfsParent |
gptkb:Bcl-2
gptkb:BCL2 |
| gptkbp:bfsLayer |
7
|